---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-066458"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:00:28.945066+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Personalis enters commercialization agreement with Tempus Labs for NeXT Personal Dx assay

## Summary
- Tempus will pay Personalis up to $12,000,000 in Market Development Fee, including a $3M activation fee.
- Personalis issued two warrants to Tempus to purchase up to 4,609,400 shares each at $1.50 and $2.50 per share.
- Tempus will market Personalis' NeXT Personal Dx assay for breast cancer, lung cancer, and immuno-oncology monitoring.
- The agreement has a five-year term with exclusivity until December 31, 2027, and includes milestones for up to $12M in fees.

## SEC filing metadata
- accession: 0000950170-23-066458
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/0000950170-23-066458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/psnl-20231125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-066458
- JSON: https://secwatch.observer/filing/0000950170-23-066458.json
- Plain text: https://secwatch.observer/filing/0000950170-23-066458.txt

## Key facts
- Material Agreements
  Personalis, Inc. entered into Commercialization and Reference Laboratory Agreement with Tempus Labs, Inc. valued at up to $12,000,000 in the aggregate (effective 2023-11-25).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Tempus Labs, Inc.
  - Value: up to $12,000,000 in the aggregate
  - Effective: 2023-11-25
  source text: On November 25, 2023 (the “Effective Date”), Personalis, Inc. (the “Company”) and Tempus Labs, Inc. (“Tempus”) entered into a Commercialization and Reference Laboratory Agreement (the “Tempus Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/0000950170-23-066458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.